Yayın: Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats
| dc.contributor.buuauthor | Hamurtekin, Emre | |
| dc.contributor.buuauthor | Bağdaş, Deniz | |
| dc.contributor.buuauthor | Gürun, M. Sibel | |
| dc.contributor.department | Tıp Fakültesi | |
| dc.contributor.department | Farmakoloji ve Klinik Farmakoloji Ana Bilim Dalı | |
| dc.contributor.researcherid | AAG-8716-2019 | |
| dc.contributor.scopusid | 8717648500 | |
| dc.contributor.scopusid | 15062425700 | |
| dc.contributor.scopusid | 55664349700 | |
| dc.date.accessioned | 2022-10-31T06:40:25Z | |
| dc.date.available | 2022-10-31T06:40:25Z | |
| dc.date.issued | 2007-04-24 | |
| dc.description.abstract | Cytidine-5'-diphosphate choline (CDP-choline; citicoline) is an essential endogenous compound normally produced by the organism and is a source of cytidine and choline. Our recent studies on acute pain models demonstrate that intracerebroventricularly administered CDPcholine produces antinociception via supraspinal alpha-7 nicotinic acetylcholine receptors-mediated mechanism in rats. However, it remains to be elucidated which other supraspinal mechanisms are involved in the antinociceptive effect of CDP-choline. In this study, we investigated the role of the supraspinal opioidergic, GABAergic, alpha-adrenergic and serotonergic receptors in CDP-choline-induced antinociception. The antinociceptive effect of CDP-choline was evoked by the intracerebroventricular (i.c.v.) administration. Two different pain models were utilized: thermal paw withdrawal test and mechanical paw pressure test. The i.c.v. administration of CDP-choline (0.5, 1.0 and 2.0 mu mol) produced dose-dependent antinociception. Non-specific opioid receptor antagonist naloxone (10 mu g; i.c.v.) and GABA(B) receptor antagonist CGP-35348 (20 mu g; i.c.v.) pretreatments inhibited the antinociceptive effects of CDP-choline (1.0 mu mol; i.c.v.). In contrast, the alpha-1 adrenergic receptor antagonist prazosin (20 mu g; i.c.v.), alpha-2 adrenergic receptor antagonist yohimbine (30 mu g; i.c.v.) and non-specific scrotonin receptor antagonist methysergide (20 mu g; i.c.v.) pretreatments had no effect on CDP-choline-induced antinociception in the thermal paw withdrawal test and in the mechanical paw pressure test. Therefore, it can be postulated that i.c.v. administered CDP-choline exerts antinociceptive effect mediated by supraspinal opioid and GABAB receptors in acute pain models. Furthermore, supraspinal alpha-adrenergic and serotonergic receptors do not appear to be involved in the antinociceptive effect of CDP-choline. | |
| dc.identifier.citation | Hamurtekin, E. vd. (2007). "Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats". Neuroscience Letters, 420(2), 116-121. | |
| dc.identifier.doi | 10.1016/j.neulet.2007.04.058 | |
| dc.identifier.issn | 0304-3940 | |
| dc.identifier.issn | 1872-7972 | |
| dc.identifier.issue | 2 | |
| dc.identifier.pubmed | 17531379 | |
| dc.identifier.scopus | 2-s2.0-34249330701 | |
| dc.identifier.uri | https://doi.org/10.1016/j.neulet.2007.04.058 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0304394007005095 | |
| dc.identifier.uri | http://hdl.handle.net/11452/29261 | |
| dc.identifier.volume | 420 | |
| dc.identifier.wos | 000247405500005 | |
| dc.indexed.scopus | Scopus | |
| dc.indexed.wos | SCIE | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Ireland | |
| dc.relation.journal | Neuroscience Letters | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | GABA receptors | |
| dc.subject | Nicotinic acetylcholine-receptors | |
| dc.subject | Alpha-7 nicotinic receptors | |
| dc.subject | Antinociception | |
| dc.subject | CDP-choline | |
| dc.subject | Opioid receptors | |
| dc.subject | Pain | |
| dc.subject | Morphine-induced antinociception | |
| dc.subject | Analgesic activity | |
| dc.subject | Agonists | |
| dc.subject | Release | |
| dc.subject | Antagonists | |
| dc.subject | Modulation | |
| dc.subject | Mechanisms | |
| dc.subject | Citicoline | |
| dc.subject | Diversity | |
| dc.subject | Neurosciences & neurology | |
| dc.subject.emtree | Male | |
| dc.subject.emtree | Analgesia | |
| dc.subject.emtree | Animal experiment | |
| dc.subject.emtree | Animal model | |
| dc.subject.emtree | Antinociception | |
| dc.subject.emtree | Article | |
| dc.subject.emtree | Controlled study | |
| dc.subject.emtree | Experimental model | |
| dc.subject.emtree | Nonhuman | |
| dc.subject.emtree | Serotonin antagonist | |
| dc.subject.emtree | Mechanical stimulation | |
| dc.subject.emtree | Pain | |
| dc.subject.emtree | Opiate antagonist | |
| dc.subject.emtree | Rat | |
| dc.subject.emtree | Methysergide | |
| dc.subject.emtree | 3 aminopropyl(diethoxymethyl)phosphinic acid | |
| dc.subject.emtree | Priority journal | |
| dc.subject.emtree | Thermal stimulation | |
| dc.subject.emtree | Alpha adrenergic receptor | |
| dc.subject.emtree | Citicoline | |
| dc.subject.emtree | 4 aminobutyric acid B receptor | |
| dc.subject.emtree | 4 aminobutyric acid B receptor blocking agent | |
| dc.subject.emtree | 4 aminobutyric acid receptor | |
| dc.subject.emtree | Alpha 1 adrenergic receptor | |
| dc.subject.emtree | Alpha 1 adrenergic receptor blocking agent | |
| dc.subject.emtree | Alpha 2 adrenergic receptor | |
| dc.subject.emtree | Alpha 2 adrenergic receptor blocking agent | |
| dc.subject.emtree | Naloxone | |
| dc.subject.emtree | Opiate receptor | |
| dc.subject.emtree | Prazosin | |
| dc.subject.emtree | Serotonin receptor | |
| dc.subject.emtree | Yohimbine | |
| dc.subject.mesh | Analgesics | |
| dc.subject.mesh | Acute disease | |
| dc.subject.mesh | Adrenergic alpha-antagonists | |
| dc.subject.mesh | Animals | |
| dc.subject.mesh | Efferent oathways | |
| dc.subject.mesh | Receptors, GABA-B | |
| dc.subject.mesh | Brain | |
| dc.subject.mesh | Cytidine diphosphate choline | |
| dc.subject.mesh | Disease models, animal | |
| dc.subject.mesh | GABA antagonists | |
| dc.subject.mesh | Receptors, GABA | |
| dc.subject.mesh | Injections,intraventricular | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Receptors,adrenergic, alpha | |
| dc.subject.mesh | Narcotic antagonists | |
| dc.subject.mesh | Rats | |
| dc.subject.mesh | Rats, sprague-dawley | |
| dc.subject.mesh | Nociceptors | |
| dc.subject.mesh | Pain | |
| dc.subject.mesh | Pain measurement | |
| dc.subject.mesh | Pain threshold | |
| dc.subject.mesh | Receptors, opioid | |
| dc.subject.mesh | Receptors, serotonin | |
| dc.subject.mesh | Serotonin antagonists | |
| dc.subject.scopus | Citicoline; Neuroprotective Agents; Glycerylphosphorylcholine | |
| dc.subject.wos | Neurosciences | |
| dc.title | Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats | |
| dc.type | Article | |
| dc.wos.quartile | Q3 | |
| dc.wos.quartile | Q3 | |
| dspace.entity.type | Publication | |
| local.contributor.department | Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Ana Bilim Dalı | |
| local.indexed.at | PubMed | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus |
Dosyalar
Lisanslı seri
1 - 1 / 1
